Advertisement

Genetic High Density Lipoprotein Deficiency States and Atherosclerosis

  • Ernst J. Schaefer
  • Judith R. McNamara
  • Carol J. Mitri
  • Jose M. Ordovas
Part of the Advances in Experimetal Medicine and Biology book series (AEMB, volume 201)

Abstract

High density, lipoprotein (HDL) as found in human plasma have a density of 1.063–1.21 g/ml, and are composed (weight percent) of approximately 50% protein, 25% phospholipid, 20% cholesterol, and 5% triglyceride (1). Fluctuations in HDL levels have been associated mainly with alterations in HDL2 (density, 1.063–1.125 g/ml), rather than HDL3 (density, 1.125–1.21 g/ml (2). Apolipoproteins (apo) A-I and A-II are the major proteins of HDL. Minor constituents include apoB, apoC-I, apoC-II, apoC-III, apoD, apoE, apoF, apoG, apoLp(a) (3–12). Apolipoprotein not only have structural roles in HDL particles, but have other functions as well. ApoA-I and apoC-I have both been reported to activate lecithin/cholesterol acyltransferase (LCAT), while apoA-II has been reported to enhance hepatic lipase activity (12–15). ApoC-II activates the enzyme lipoprotein lipase, while apoC-III has been shown to inhibit hepatic chylomicron remnant uptake (16,17). Both apoB and apoE can bind to the apoB,E receptor (LDL receptor) on various cell surfaces, while apoE also binds to the liver apoE receptor, which is essential for chylomicron remnant uptake (18,19). The low density lipoprotein (LDL) receptor appears to be crucial for regulating LDL levels in plasma, as well as for maintaining intracellular cholesterol homeostasis. HDL particles can bind to specific sites on various cell surfaces (20).

Keywords

Cholesterol Ester Premature Coronary Artery Disease Tangier Disease Intracellular Cholesterol Homeostasis Familial LCAT Deficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R. J. Havel, H. A. Eder, J. H. Bragdon, The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum, J Clin Invest 34:1345–1353 (1955).PubMedCrossRefGoogle Scholar
  2. 2.
    D. W. Anderson, A. V. Nichols, S. S. Pan, F. T. Lindgren, High density lipoprotein distribution:resolution and determination of three major components in a normal population sample, Atherosclerosis 29:161–179 (1978).PubMedCrossRefGoogle Scholar
  3. 3.
    A. J. Scanu, J. Toth, C. Edelstein, E. Stiller, Fractionation of human serum high density lipoprotein in urea solutions: evidence of polypeptide heterogeneity, Biochemistry 8:3309–3316 (1969).PubMedCrossRefGoogle Scholar
  4. 4.
    B. Shore, V. Shore, Isolation and characterization of polypeptides of human serum lipoproteins, Biochemistry 8:4510–4516 (1969).PubMedCrossRefGoogle Scholar
  5. 5.
    A. Heiberg, K. Berg, On the relationship between Lp(a) lipoprotein, “sinking pre-beta-lipoprotein” and inherited hyper-beta-lipoproteinemia, clin Genet 5:144–150 (1974).PubMedCrossRefGoogle Scholar
  6. 6.
    G. Kostner, P. Alaupovic, Studies of the composition and structure of plasma lipoproteins. Separation and quantitation of the lipoprotein families occurring in high density lipoproteins of human plasma, Biochemistry 11:3429–3433 (1972).CrossRefGoogle Scholar
  7. 7.
    A. Gustafson, P. Alaupovic, R. H. Furman, Studies of the composition and structure of serum lipoproteins. Separation and characterization of phospholipid-protein residues obtained by partial delipidation of very low density lipoproteins of human serum, Biochemistry 5:632–640 (1966).PubMedCrossRefGoogle Scholar
  8. 8.
    W. V. Brown, R. I. Levy, D. S. Fredrickson, Further separation of the apoproteins of the human plasma very low density lipoproteins, Biochem Biophys Acta 280:573–575 (1970).Google Scholar
  9. 9.
    W. J. McConathy, P. Alaupovic, Studies on the isolation and partial characterization of apolipoprotein and lipoprotein D in human plasma, Biochemistry 15:515–552 (1976).PubMedCrossRefGoogle Scholar
  10. 10.
    F. Shelburne, S. Quarfordt, A new apoprotein of human plasma very low density lipoproteins, J Biol Chem 249:1428–1432 (1974).PubMedGoogle Scholar
  11. 11.
    S. O. Olofsson, W. J. McConathy, P. Alaupovic, Isolation and partial characterization of a new acidic apolipoprotein (apolipoprotein F) from high density lipoproteins of human plasma, Biochemistry 17:1032–1036 (1978).PubMedCrossRefGoogle Scholar
  12. 12.
    M. Ayrault-Jarrier, J. Alix, J. Polonovski, Une nouvelle proteine des lipoproteines du serum hamain:isolement et caracterisation partielle d’une apolipoproteine, G Biochimie 60:65–71 (1978).CrossRefGoogle Scholar
  13. 13.
    C. J. Fielding, V.G. shore, P.E. Fielding, A protein co-factor of lecithin:cholesterol acyltransferase, Biochem Biophy Res Commun 46:1493–1498 (1972).CrossRefGoogle Scholar
  14. 14.
    A. K. Soutar, G. W. Garner, G. N. Baker, et al, Effect of the human plasma apolipoproteins and phosphatidyl-choline acyl donor on the activity of lecithin:cholesterol acyltransferase, Biochemistry 14:3057–3064 (1975).PubMedCrossRefGoogle Scholar
  15. 15.
    C. E. Jahn, J. O. Osborne, E. J. Schaefer, H. B. Brewer Jr., ApoA-II specific activation of hepatic lipase enzymatic activity identification of a major HDL apoprotein as the activating plasma component in vitro, Eur J Biochem 131:25–29 (1983).PubMedCrossRefGoogle Scholar
  16. 16.
    J. C. LaRosa, R. I. Levy, P. N. Herbert, S. E. Lux, D. S. Fredrickson, A specific apoprotein activator for lipoprotein lipase, Biochem Biophy Res Comm 41:57–62 (1970).CrossRefGoogle Scholar
  17. 17.
    F. Shelburne, J. Hanks, W. Myers, S. Quarfordt, Effects of apoproteins on hepatic uptake of triglyceride emulsions in the rat, J Clin Invest 65:652–658 (1980).PubMedCrossRefGoogle Scholar
  18. 18.
    M. S. Brown, S. E. Dana, J. L. Goldstein, Regulation of 3-hydroxy-3 methylglutaryl coenzyme A reductase activity in cultured human fibroblasts: Comaprison of cells from a normal subject and a patient with homozygous familial hypercholesterolemia, J Biol Chem 249:789–796 (1974).PubMedGoogle Scholar
  19. 19.
    B. C. Sherrill, T. L. Innerarity, R. W. Mahley, Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor, J Biol Chem 255:1804–1807 (1980).PubMedGoogle Scholar
  20. 20.
    R. Biesbroeck, J. F. Oram, J. J. Albers, E. L. Bierman, Specific high affinity binding of high density lipoproteins in cultured human skin fibroblasts and arterial smooth muscle cells, J Clin Invest 71:525–539 (1983).PubMedCrossRefGoogle Scholar
  21. 21.
    A. L Wu, H. G. Windmueller, Relative contributions by liver and intestine to individual apolipoproteins in the rat, J Biol Chem 254:7316–7322 (1979).PubMedGoogle Scholar
  22. 22.
    D. W. Anderson, E. J. Schaefer, T. J. Bronzert, F. T. Lindgren, T. Forte, T. E. Stanze, G. D. Nibalck, L. A. Zech, H. B. Brewer Jr., Transport of apolipoprotein A-I and A-II by human thoracid duct lymph, J Clin Invest 67:857–866 (1981).PubMedCrossRefGoogle Scholar
  23. 23.
    J. Marsh, Apoproteins of the lipoproteins in a nonrecirculating perfusate of rat liver, J Lipid Res 17:85–90 (1976).PubMedGoogle Scholar
  24. 24.
    T. E. Felker, M. Fairnaru, R. L. Hamilton, R. J. Havel, Secretion of the arginine-rich and A-I apolipoproteins by the isolated perfused rat liver, J Lipid Res 18:465–473 (1977).PubMedGoogle Scholar
  25. 25.
    D. W. Bilheimer, S. Eisenberg, R. I. Levy, The metabolism of very low density lipoprotein proteins.1.Preliminary in vitro and vivo observations, Biochim Biophy Acta 260:212–221 (1972).CrossRefGoogle Scholar
  26. 26.
    S. Eisenberg, D. W. Bilheimer, R. I. Levy, F. T. Lingren, On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein, Biochem Biophys Acta 326:361–377 (1973).PubMedCrossRefGoogle Scholar
  27. 27.
    M. C. Glangeaud, S. Eisenberg, T. Olivecrona, Very low desnity lipoprotein dissociation of apolipoprotein C during lipoprotein lipase induced lipolysis, Biochim Biophys Acta 48:23–35 (1977).Google Scholar
  28. 28.
    R. M. Glickman, P. H. R. Green, The intestine as a source of apolipoprotein A-I, Pro Natl Acad Sci USA 74:2569–2573 (1977).CrossRefGoogle Scholar
  29. 29.
    E. J. Schaefer, L. J. Jenkins, H. B. Brewer Jr., Human chylomicron apolipoprotein metabolism, Biochem Biophs Res Commun 80:405–412 (1978).CrossRefGoogle Scholar
  30. 30.
    T. G. Redgrave, D. M. Small, Quantitation of the transfer of surface phospholipid of chylomicrons to the high density lipoprotein fraction during the catabolism of chylomicrons in the rat, J Clin Invest 64:162–171 (1979).PubMedCrossRefGoogle Scholar
  31. 31.
    E. J. Schaefer, M. G. Wetzel, G. Bengtsson, R. B. Scow, H.B. Brewer Jr., T. Olivecrona, Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis, J Lipid Res 23:1259–1273 (1982).PubMedGoogle Scholar
  32. 32.
    E. J. Schaefer, L. A. Zech, L. L. Jenkins, R. A. Aamodt, J. J. Bronzert, E. A. Rubalcaba, F. T. Lindgren, H. B. Brewer Jr., Human apolipoprotein A-I and A-II metabolism, J Lipid Res 23:850–862 (1982).PubMedGoogle Scholar
  33. 33.
    C. K. Glass, R. C. Pittman, G. A. Keller, D. Steinberg, Tissue sites of degradation of apoprotein A-I in the rat, J Biol Chem 258:7161–7167 (1983).PubMedGoogle Scholar
  34. 34.
    L. A. Zech, E. J. Schaefer, L. L. Jenkins, E. A. Rubalcaba, T. J. Bronzert, R. L. Aamodt, H. B. Brewer Jr., Metabolism of human apolipoproteins A-I and A-II, compartmental models, J Lipid Res 34:60–71 (1983).Google Scholar
  35. 35.
    D. P. Barr, E. M. Russ, H. A. Eder, Protein lipid relationships in human plasma. II. In atherosclerosis and related conditions, Am J Med 11:480–492 (1951).PubMedCrossRefGoogle Scholar
  36. 36.
    G. J. Miller, N. F. Miller, Plasma-high density lipoprotein concentration and development of ischemic heart disease, Lancet 1:16–20 (1975).PubMedCrossRefGoogle Scholar
  37. 37.
    G. G. Rhoads, C. L. Gulbrandsen, A. Kagan, Serum lipoproteins and coronary heart disease in a population of Hawaii Japaneses men, N Engl J Med 294:293–298 (1976).PubMedCrossRefGoogle Scholar
  38. 38.
    N. E. Miller, O. H. Forde, D. S. Thelle, The Tromso Heart Study:high density lipoprotein and coronary heart disease:a prospective case control study, Lancet 55:767–772 (1977).Google Scholar
  39. 39.
    W. Castelli, J. T. Doyle, T. Gordon, HDL cholesterol and other lipids in coronary heart disease, The Cooperative Lipoprotein Phenotyping Study, Circulation 55:767–772 (1977).PubMedCrossRefGoogle Scholar
  40. 40.
    R. M. Krauss, Regulation of high density lipoprotein levels in lipid disorder, R. Havel, ed., Medical Clin North American 66(2):403–430 (1982).Google Scholar
  41. 41.
    E. J. Schaefer, D. A. Foster, L. A. Zech, H. B. Brewer Jr., R. I. Levy, The effect of estrogen administration of plasma lipoprotein metabolism in premenopausal females, J Clin Endocrinal Metab 57:262–267 (1983).CrossRefGoogle Scholar
  42. 42.
    E. J. Schaefer, Clinical, biochemical and genetic features in familial disorders of high density lipoprotein deficiency, Arteriosclerosis 4:303 (1984).PubMedCrossRefGoogle Scholar
  43. 43.
    C. Vergani, A. Bettale, Familial hypoalphalipoproteinemia, Clin Chim Acta 114:45–52 (1981).PubMedCrossRefGoogle Scholar
  44. 44.
    C. J. Glueck, S. R. Daniels, S. Bates, C. Benton, T. Tracy, J. L. H. C. Third, Pediatric victims of unexplained stroke and their families: familial lipid and lipoprotein abnormalities, Pediatrics 69:308–316 (1982).PubMedGoogle Scholar
  45. 45.
    S. R. Daniels, S. Bates, R. R. Lukin, C. Benton, J. L. H. C. Third, C. J. Glueck, Cerebrobascular arteriopathy (arteriosclerosis) and ischemic childhood stroke, Stroke 13:360–365 (1982).PubMedCrossRefGoogle Scholar
  46. 46.
    J. H. L. C. Third, J. Montag, M. Flynn, J. Freidel, P. Laskarzewski, C. J. Glueck, Primary and familial hypoalphalipoproteinemia, Metabolism 33:136–146 (1984).PubMedCrossRefGoogle Scholar
  47. 47.
    N. Fidge, P. Nestel, T. Ishikawa, M. Reardon, T. Billington, Turnover of apoproteins A-I and A-II of human high density lipoprotein and the relationahip to other lipoproteins in normal and hyperlipidemic individuals, Metabolism 29:643–653 (1980).PubMedCrossRefGoogle Scholar
  48. 48.
    J. M. Ordovas, E. J. Schaefer, D. Salem, R. Ward, C. J. Glueck, C. Vergani, P. W. F. Wilson, S. K. Karathanasis, Apolipoprotein A-I gene polymorphism is the 3’ flanking region associated with familial hypoalphalipoproteinemia and premature coronary artery disease, N Engl J Med (in press).Google Scholar
  49. 49.
    K. R. Norum E. Gjone, Familial plasma lecithin:cholesterol acyltransferase deficiency. Biochemical study of a new inborn error of metabolism, Scand J Clin Lab Invest 20:231–236 (1967).CrossRefGoogle Scholar
  50. 50.
    E. Gjone, K. R. Norum, Familial serum cholesterol ester deficiency: clinical study of a patient with a new syndrome, Acta Med Scand 183:107–115 (1968).PubMedCrossRefGoogle Scholar
  51. 51.
    J. A. Glomset, K. R. Norum, E. Gjone, Familial lecithin:cholesterol acyltransferase deficiency, In: J. B. Stanburg, J. B. Wyngaarden, D. S. Fredrickson, J. L. Goldstein, M. S. Brown, eds. The MetabolicBasis of Inherited Disease, 5th ed., New York: McGraw-Hill 643–654 (1983).Google Scholar
  52. 52.
    L. S. Carlson, B. Philipson, Fishe-eye disease:a new familial condition associated with massive corneal opacitites and dyslipoproteinemia, Lancet 8149:921–925 (1979).CrossRefGoogle Scholar
  53. 53.
    L. A. Carlson, Fish-eye disease: a new familial condition with massive corneal opacities and dyslipoproteinemia, Eur J Clin Invest 12:41–52 (1982).PubMedCrossRefGoogle Scholar
  54. 54.
    G. Grancheschini, C. R. Sirtori, A. Capurso, K. H. Weisgraber, R. W. Mahley, A-IMilano apoprotein. Decreased high density lipoprotein cholesterol ieveis with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family, J Clin Invest 66:892–990 (1980).CrossRefGoogle Scholar
  55. 55.
    K. H. Weisgraber, T. P. Bersot, R. W. Mahley, G. Francheschini, C. R. Sirtori, A-IMilano apoprotein, isolation and characterization of a cysteine-containmg variant of the A-I apoprotein from human high density lipoprotein, J Clin Invest 66:901–909 (1980).PubMedCrossRefGoogle Scholar
  56. 56.
    G. Utermann, G. Feussner, G. Franceschini, J. Haas, A. Steinmetz, Genetic variants of group A apolipoproteins. Lipid methods for screening and characterization without ultracentrifugation, J Biol Chem 257:501–507 (1982).PubMedGoogle Scholar
  57. 57.
    S. C. Rall Jr., K. H. Weisgraber, R. W. Mahley, Y. Ogawa, C. J. Fielding, G. Utermann, J. Haas, A. Steinmetz, H. J. Menzel, G. Assmann, Abnormal lecithin:cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine is deleted, J Biol Chem 259:10063–10070 (1984).PubMedGoogle Scholar
  58. 58.
    H. J. Menzel, R. G. Kladetzky, G. Assmann, One step screening method for the polymorphism of apolipoproteins A-I, A-II, and A-IV, J Lipid Res 23:915–922 (1982).PubMedGoogle Scholar
  59. 59.
    H. T. Mezel, G. Assmann, S. C. Rall Jr., K. H. Weisgraber, R. W. Mahley, Human apoliporptein A-I polymorphism, J Biol Chem 259:3070–3076 (1984).Google Scholar
  60. 60.
    G. Ghiselli, J. A. Summerfield, E. J. Schaefer, C. Sirtori, E. A. Jones, H. B. Brewer Jr., Abnormal catabolism of apoA-IMilano (abstr) Clin Res 30:291A (1982).Google Scholar
  61. 61.
    A. Rees, C. C. Shoulders, J. Stocks, D. J. Galton, F. E. Baralle, DNA polymorphism adjacent to the human apoprotein A-I gene:relation to hypertriglyceridemia, Lancet 1:444–446 (1983).PubMedCrossRefGoogle Scholar
  62. 62.
    G. R. Lindeskog, A. Gustafson, L. Enerback, Serum lipoprotein deficiency in diffuse normolipemic plan xanthoma, Arch Dermatol 106:529–532 (1972).PubMedCrossRefGoogle Scholar
  63. 63.
    A. Gustafson, W. McConathy, P. Alaupovic, M. D. Curry, B. Persson, Identification of apoprotein families in a variant of human plasma apolipoprotein A deficiency, Scand J Clin Lab Invest 39:377–388 (1979).PubMedCrossRefGoogle Scholar
  64. 64.
    D. S. Fredrickson, P. H. Altrocchi, L. C. Avioli, Tangier disease: combined clinical staff conference at the National Institutes of Health, Ann Intern Med 55:1016–1031 (1961).Google Scholar
  65. 65.
    D. A. Frederickson, The inheritance of high density lipoprotein deficiency (Tangier disease) J Clin Invest 43:228–236 (1964).CrossRefGoogle Scholar
  66. 66.
    P. N. Herbert, G. Assmann, A. M. Gotto Jr., D. S. Fredrickson, Familial lipoprotein deficiency:abetalipoproteinemia, hypobetalipo-proteinemia, and Tangier disease In: J. B. Wyngaarden, D. S. Fredrickson, J. Goldstein, M. Brown eds. The Metabolic Basis of Inherited Disease 5th ed. New York: McGraw-Hill 589–621 (1982).Google Scholar
  67. 67.
    E. J. Schaefer, L. A. Zech, D. S. Schwartz, H. B. Brewer Jr., Coronary heart disease prevalence and other clinical features in familial high density lipoprotein deficiency (Tangier disease), Ann Inter Med 93:261–266 (1980).Google Scholar
  68. 68.
    L. O. Henderson, P. N. Herbert, D. S. Fredrickson, R. J. Heinen, Abnormal concentration and anomalous distribution of apolipoprotein A-I in Tangier disease, Metabolism 27:165–174 (1978).PubMedCrossRefGoogle Scholar
  69. 69.
    P. Alaupovic, E. J. Schaefer, W. J. McConathy J. S. Fesmire, H. B. Brewer Jr., Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease), Metabolism 30:809–816 (1981).CrossRefGoogle Scholar
  70. 70.
    V. I. Zannis, A. M. Lees, R. S. Lees, J. L. Breslow, Abnormal apoA-I isoprotein composition in patients with Tangier disease, J Biol Chem 257:4978–4986 (1982).PubMedGoogle Scholar
  71. 71.
    H. B. Brewer Jr., T. Fairwell, L. Kay, M. Meng, R. Ronan, S. Law, J. A. Light, Human plasma proapoA-I:isolation and amino-terminal sequence, Biochem Biophys Res Comm 113:626–632 (1983).PubMedCrossRefGoogle Scholar
  72. 72.
    E. J. Schaefer, C. B. Blum, R. I. Levy, et al, Metabolism of high density lipoprotein in Tangier disease, N Engl J Med 299:905–910 (1978).PubMedCrossRefGoogle Scholar
  73. 73.
    E. J. Schaefer, D. W. Anderson, L. A. Zech, et al, Metabolism of high density lipoprotein subfractions in Tangier disease following the infusion of high density lipoproteins, J Lipid Res 22:217–218 (1981).PubMedGoogle Scholar
  74. 74.
    G. Assmann, A. Capurso, E. Smootz, K. Wellner, apoprotein A metabolism in Tangier disease, Atherosclerosis 30:321–332 (1978).PubMedCrossRefGoogle Scholar
  75. 75.
    R. A. Norum, J. B. Lakier, S. Goldstein, A. Angel, R. B. Goldberg, W. D. Black, D. K. Noffze, P. J. Dolphin, J. Edelglass, D. D. Borograd, P. Alaupovic, Familial deficiency of apolipoproteins A-I and apoC-III and precocious coronary artery disease, N Engl J Med 306:1513–1519 (1983).CrossRefGoogle Scholar
  76. 76.
    S. K. Karathanasis, R. A. Norum, V. I. Zannis, J. L. Breslow, An inherited polymorphism in the human apolipoprotin A-I gene locus related to the development of atherosclerosis, Nature 301:718–720 (1983).PubMedCrossRefGoogle Scholar
  77. 77.
    R. A. Norum, P. J. Dolphin, P. Alaupovic, Familial deficiency of apolipoproteins A-I and C-III and precocious coronary artery disease: family study in Latent Dyslipoproteinemias and Atherosclerosis J. L. DeGennes ed, Raven Press, New York 289–295 (1984).Google Scholar
  78. 78.
    E. J. Schaefer, W. H. Heaton, M. G. Wetzel, H. B. Brewer Jr., Plasma apolipoprotein A-I absence assoicated with a marked reduction of high density lipoproteins and premature coronary artery disease, Arteriosclerosis 2:16–26 (1982).PubMedCrossRefGoogle Scholar
  79. 79.
    E. J. Schaefer, J. M. Ordovas, S. Law, G. Ghiselli, M. L. Kashyap, L. S. Srivastava. W. H. Heaton, J. J. Albers, W. E. Conners, H. B. Brewer Jr., Familial apolipoprotein A-1 and C-III deficiency, variant II, J Lipid Res 26:1089–1101 (1985).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • Ernst J. Schaefer
    • 1
  • Judith R. McNamara
    • 1
  • Carol J. Mitri
    • 1
  • Jose M. Ordovas
    • 1
  1. 1.Lipid Metabolism LaboratoryHuman Nutrition Research Center on Aging at Tufts UniversityBostonUSA

Personalised recommendations